MaxCyte Inc
LSE:MXCT
MaxCyte Inc
Net Income (Common)
MaxCyte Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MaxCyte Inc
LSE:MXCT
|
Net Income (Common)
-$37.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Net Income (Common)
$6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
Danaher Corp
NYSE:DHR
|
Net Income (Common)
$8.1B
|
CAGR 3-Years
21%
|
CAGR 5-Years
27%
|
CAGR 10-Years
12%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Net Income (Common)
$788.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
Agilent Technologies Inc
NYSE:A
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Net Income (Common)
$1.4B
|
CAGR 3-Years
69%
|
CAGR 5-Years
39%
|
CAGR 10-Years
20%
|
See Also
What is MaxCyte Inc's Net Income (Common)?
Net Income (Common)
-37.9m
USD
Based on the financial report for Dec 31, 2023, MaxCyte Inc's Net Income (Common) amounts to -37.9m USD.
What is MaxCyte Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-34%
Over the last year, the Net Income (Common) growth was -61%. The average annual Net Income (Common) growth rates for MaxCyte Inc have been -47% over the past three years , -34% over the past five years .